Skip Navigation LinksHome > May 2007 - Volume 39 - Issue 5 > Is Peroxisome Proliferator‐ activated Receptor (PPAR) Genoty...
Medicine & Science in Sports & Exercise:
doi: 10.1249/01.mss.0000273864.17181.8e
A-37 Free Communication/Poster -Weight Loss: MAY 30, 2007 7:30 AM - 12:30 PM ROOM: Hall E

Is Peroxisome Proliferator‐ activated Receptor (PPAR) Genotype A Useful Predictor For Body‐weight Reduction?: 1505: Board #268 May 30 9:30 AM ‐ 11:00 AM

Matsuo, Tomoaki1; Nakata, Yoshio1; Okura, Tomohiro1; Hotta, Kikuko2; Tanaka, Kiyoji FACSM1

Free Access
Collapse Box

Author Information

1University of Tsukuba, Tsukuba, Japan.

2Institure of Physical and Chemical Research, Yokohama, Japan.


An individual's genetic information, which is available as an additional determinant for body-weight reduction, may be able to modify the weight reduction program. Single-nucleotide polymorphism (SNP) is one of the important factors to explain various differences in human individuals. Peroxisome proliferator activated receptor (PPAR) plays a key role in the regulation of lipid and glucose metabolisms and body fat distribution. Several researchers suggest a significant relationship between the PPAR genotype and body-weight change. It is unclear, however, whether PPAR genotype is a useful as decisive factor in weight-reduction.

PURPOSE: To investigate the relationship between the PPAR genotype and body-weight change in response to a 14-week intervention, and to quantify the contribution of PPAR genotype as additional information for weight reduction program.

METHODS: In total, 282 middle-aged Japanese women (age, 48.9±9.1 years; body mass index, 27.1±3.1 kg/m2) participated in a 14-week diet and exercise intervention program as subjects. Genetic information about PPAR was analyzed (7 SNPs of peroxisome proliferator activated receptor γ; PPARG, 3 SNPs of peroxisome proliferator activated receptor α; PPARA and 10 SNPs of peroxisome proliferator activated receptor γ coactivator 1; PPARGC1).

RESULTS: Body-weight decreased significantly (−7.9±3.0 kg, −11.9±4.0%) following the intervention. An analysis of covariance (ANCOVA) was used to test for differences in the amount of body-weight reduction among each of the genotypes using baseline body mass index as a covariate. As a result, only one SNP (PPARG) had a strong relationship (p = 0.0009) with the amount of body-weight reduction. In a multiple regression model, baseline body mass index accounted for 12% of the total variance in body-weight change. The percentage increased to 17% when PPAR genotype was included the model.

CONCLUSIONS: These data suggest that PPAR genotype influences the change in body-weight in response to a 14-week weight reduction intervention among obese middle-aged Japanese women. The PPAR genotype accounted for additional 5% of the total body-weight reduction variance.

©2007The American College of Sports Medicine


Article Tools


Article Level Metrics

Connect With Us